Indeed, this idea has recently been supported by experimental studies in mouse models for glioblastoma and pancreatic cancer showing that CSF-1/CSF-1R pathway blockade can shift TAM polarization toward an anti-tumor phenotype, resulting in enhanced CD8+ T cell-mediated anti-tumor immunity (132, 133). The gene discussed is CD8A; the disease is neoplasm.